Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 and Temozolomide in Metastatic Pancreatic Neuroendocrine Tumors
NCT02943733Phase 1Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2017
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil in Pancreatic neuroendocrine tumor (PanNET), sponsored by University of Wisconsin–Madison. Primary endpoints: Maximum Tolerated Dose at 2 years and Overall Response Rate at 5 years. Started Aug 2017; status: terminated.
02
Drugs
trifluridine + tipiracil
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02943733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943733.